Please login to the form below
Hodgkin lymphoma
This page shows the latest Hodgkin lymphoma news and features for those working in and with pharma, biotech and healthcare.
Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
Gilead Science and Kite, a Gilead company, have announced that the National Institute for Health and Care Excellence (NICE) has recommended Yescarta (axicabtagene ciloleucel) to treat certain forms of lymphoma. ... DLBCL and PMBCL are both aggressive
Latest news
-
Roche shares phase 3 Polivy data for previously untreated diffuse large B-cell lymphoma
The most common form of non-Hodgkin lymphoma (NHL), DLBCL accounts for about one in three cases of NHL. ... This was evaluated by the investigator using the Lugano Response Criteria for malignant lymphoma.
-
FDA approves Seagen’s Adcetris combination for paediatric patients with Hodgkin lymphoma
Hodgkin lymphoma (cHL), in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide (AVE-PC). ... The study enrolled 587 patients aged from two to 21 years across 151 institutions who had previously untreated Hodgkin
-
BeiGene’s Brukinsa receives EC approval for marginal zone lymphoma
BeiGene’s Brukinsa (zanubrutinib) has been approved by the European Commission (EC) for the treatment of adult patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL) who have received at ... BTK inhibitor for marginal zone lymphoma in
-
AbbVie submits application for lymphoma therapy epcoritamab to EMA
of investigational epcoritamab in adult patients with relapsed, progressive or refractory CD20+ mature B-cell non-Hodgkin's lymphoma (NHL), including DLBCL. ... large B-cell lymphoma and diffuse large B-cell lymphoma who have limited treatment options.
-
Kite’s CAR-T therapy Yescarta granted EC approval in second-line lymphoma
Moreover, improvements in EFS with Yescarta were consistent across key patient subgroups, including elderly patients, primary refractory patients, HGBL, and double-expressor lymphoma patients. ... DLBCL is the most common subtype of non-Hodgkin lymphoma
More from news
Approximately 9 fully matching, plus 222 partially matching documents found.
Latest Intelligence
-
Growing evidence supports the important role of biosimilars in healthcare
The fatality rate was higher for patients with lung cancer and non-Hodgkin Lymphoma, at 15.7% and 9.4%, respectively. ... It also builds on previous studies demonstrating the cost-effectiveness of Zarxio as primary prophylaxis within patients with lung
-
Chinese biotech’s global ambitions
CDA). The company is filing first for patients with relapsed/refractory classical Hodgkin’s lymphoma (R/R cHL) – a niche indication not yet taken in China by Keytruda and Opdivo, which
-
Deal Watch November 2016
relapsed or refractory aggressive CD19+ Non-Hodgkin Lymphoma.
-
Deal Watch June 2016
on B-cell tumor cells, including chronic lymphocytic leukaemia (CLL) and non-Hodgkin lymphoma (NHL) cells).
-
Forging a path in specialty care
Adcetris (for Hodgkin Lymphoma), Entyvio (for ulcerative colitis and Crohn's Disease) and future compound Ninlaro (an oral protease inhibitor for relapsed/refractory multiple myeloma) which was approved by the FDA
More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.
Latest appointments
-
Charles Morris appointed chief development officer at ImmunoGen
cancers that over-express folate receptor 1, and IMGN529 - in phase I testing for the treatment of non-Hodgkin's lymphoma.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Australian Flu and the dilemma of naming diseases
Naming diseases after people, places and animals has been common practice throughout the world for centuries, from the more current examples of Swine flu and Lyme disease to 19th century ... s Lymphoma and Parkinsons.
-
Therapy Watch expands oncology and IBD portfolios
Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer
-
Therapy Watch expands its oncology portfolio
Therapy Watch SCCHN is part of a wider portfolio which covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer (PCa), Renal
-
Oncology drugs under AMNOG
Pixuvri: Polycomparator segmentation by the G-BA removes statistical power. Cell Therapeutics gained European approval for Pixuvri (pixantrone) in non-Hodgkin’s B-cell lymphoma, on the basis of a trial
More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- World Health Organization releases latest set of COVID-19 guidelines
- BeiGene’s Brukinsa receives FDA approval for chronic lymphocytic leukaemia
- Europe’s cancer community publishes new report on transforming patient care
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- Eli Lilly announces $450m investment in US manufacturing site
- EU outlines measures to mitigate antibiotic shortage across Europe
- Innovative Trials comments on extra funding to increase access to clinical trials for cancer patients
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- JCVI recommends autumn COVID-19 vaccine booster for those at highest risk
- MIT researchers develop AI model to detect future lung cancer risk
- Merging global and local pharmacovigilance operations into a successful integrated approach
- Diversifying Healthcare AI with Federated Learning
- World Health Organization releases latest set of COVID-19 guidelines
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- EU outlines measures to mitigate antibiotic shortage across Europe
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Merging global and local pharmacovigilance operations into a successful integrated approach
PMHub
Medscape Education Global
Medscape delivers dynamic, innovative education to optimize learner engagement and patient outcomes worldwide....
Latest intelligence
- Virtual Steering Committee & Peer Influence Program
- In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
- Meeting healthcare’s rising challenges
- The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
- Report gives insights to address gaps in HCP engagement
- How does Pharma-HCP engagement need to evolve in today's digital landscape?...
